- Regenerative medicine company Orthocell (OCC) has granted a new U.S. divisional patent for CelGro
- The healthcare stock also focusses on regenerating mobility in patients by developing products for the repair of soft tissue injuries.
- CelGro, a customisable collagen medical device manufactured by the company at its facility in WA using the company’s SMRT tissue engineering process
- The new U.S. divisional patents expire in June 2033 and provide additional intellectual property to protect the CelGro platform
- CelGro dental, recently renamed Striate+, the first product from the CelGro platform technology to gain U.S., European and Australian approval
- Orthocell is down 1.79 per cent, trading at 55 cents
